Value of Doppler Ultrasonography in Assessing the Efficacy of Diabetic Retinopathy: A Retrospective Analysis.

Objective: To investigate the value of Doppler ultrasound in evaluating the efficacy of diabetic retinopathy. Methods: A retrospective analysis was conducted on 90 hospitalized patients with type 2 diabetes from January 2019 to January 2020. The patients were divided into two groups: 34 cases without retinopathy and 56 cases with diabetic retinopathy. Clinical data and Doppler ultrasonography results were collected and analyzed to evaluate the value of Doppler ultrasound. Results: After treatment, various indicators, including blood glucose, HbA1c, FPG, 2hFPG, HOMA-IR, and FINS, showed significant improvement in both groups (P < .05). There was no significant difference before and after treatment (P > .05). Before treatment, the retinopathy group exhibited significantly different central artery parameters: PSA (8.35 ± 1.08), EDV (5.80±0.62), RI (1.53 ± 0.25), compared to patients without retinopathy: PSA (13.61 ± 1.80), EDV (7.23 ± 0.51), RI (0.85 ± 0.02) (t = 12.019, 11.631, 11.461, P = .01, .01, .00), respectively. After treatment, the central artery parameters improved in both groups. The retinopathy group showed PSA (10.44 ± 0.26), EDV (6.84 ± 0.85), RI (1.01 ± 0.04), while patients without retinopathy exhibited PSA (15.13 ± 1.20), EDV (8.50 ± 0.80), RI (0.71 ± 0.08) (t = 15.94, 12.01, 13.32, P = .01, .01, .01), respectively. Similarly, before treatment, the retinopathy group had different central artery parameters: PSA (30.35 ± 5.15), EDV (8.85 ± 1.67), RI (1.53 ± 0.25), compared to patients without retinopathy: PSA (34.41 ± 5.20), EDV (11.34 ± 2.56), RI (0.88 ± 0.15) (t = 12.108, 11.542, 11.57, P = .01, .01, .01), respectively. After treatment, the central artery parameters improved in both groups. The retinopathy group showed PSA (33.26 ± 4.27), EDV (9.37 ± 1.86), RI (0.98 ± 0.35), while patients without retinopathy exhibited PSA (36.15 ± 4.24), EDV (13.51 ± 2.13), RI (0.76 ± 0.23) (t = 13.84, 12.14, 10.11, P = .01, .01, .01), respectively. Conclusions: Color Doppler ultrasound monitoring of fundus hemodynamic parameters can accurately reflect the changes in blood vessels in diabetic eyes. It provides real-time and objective evaluation of fundus hemodynamic indexes. This technology demonstrates high repeatability and simple operation, making it valuable for the non-invasive detection of early retinopathy.

Efficacy of brinzolamide in the initial management of acute primary angle closure: A randomized controlled trial.

WHAT IS KNOWN AND OBJECTIVE?: Since comprehensive medication has an important role in the initial management of patients presenting with acute primary angle closure, it is necessary to analyse the effect of each drug on alleviating the disease. This study aimed to evaluate the intraocular pressure-lowering effect of brinzolamide in the sequential treatment of acute primary angle closure. METHODS: In this randomized double-blind controlled trial, a total of 131 eyes of 125 consecutive patients who presented with their first episode of acute primary angle closure were recruited and received sequential treatment. In this treatment, in the absence of remission, anti-glaucoma drugs, anterior chamber paracentesis and argon laser peripheral iridoplasty are used sequentially. The patients were randomized to receive either brinzolamide or normal saline as a placebo. The primary outcomes were decreased intraocular pressure, success rate and treatment time. RESULTS AND DISCUSSION: There was no statistically significant difference in the decreased level of intraocular pressure between the two groups at 6, 12 or 24 h after the start of treatment (p-values were 0.526, 0.206 and 0.130 respectively). The success rate and treatment time were also not significantly different between the groups. No adverse side effects of brinzolamide were observed in the brinzolamide group. WHAT IS NEW AND CONCLUSION?: In patients with a first episode of acute primary angle closure, brinzolamide did not improve the effectiveness of the sequential treatment for reducing the intraocular pressure levels or shortening the treatment time within the first 24 h of initiating therapy.

A system review and meta-analysis of the treatment of acute angle-closure glaucoma under optical coherence tomography.

BACKGROUND: A meta-analysis was conducted to investigate the value of treatment-related indicators of acute angle-closure glaucoma (AACG) based on optical coherence tomography (OCT) to evaluate the curative effect. METHODS: Articles on the treatment of AACG in clinical research of OCT published from January 2010 to June 2020 were retrieved from the PubMed, Web of Science, and Spring databases. RevMan 5.3 software was used for the meta-analysis of the relevant data. The angle opening distance (AOD), trabecular-iris space area (TISA), angle recess area (ARA), anterior chamber depth (ACD), anterior chamber width (ACW), anterior chamber area (ACA), anterior chamber volume (ACV), lens vault (LV), iris thickness 750 (IT750), intraocular pressure (IOP), and pupil diameter (PD) values were observed and compared before and after the treatment. RESULTS: A total of 12 articles were included in the meta-analysis. The results indicated that patients' ACD, I-Area, IOP, and PD values were lower after treatment than before treatment [mean deviation (MD): -0.32, 0.12, -0.04, 13.55, 0.30; 95% confidential interval (CI): -0.55 to -0.08, 0.04 to 0.1, -0.09 to 0.01, 4.71 to 22.39, 0.09 to 0.529; Z=2.66, 3.06, 1.39, 3, 2.75, and P=0.008, 0.002, 0.16, 0.003, 0.006, respectively]. The ACA, ACV, ARA, AOD750, and TISA500 values were higher after treatment than before treatment (MD: -3.22, -2.90, -0.03, -0.05, -0.01; 95% CI: -5.07 to -1.38, -5.44 to -0.36, -0.05 to -0.02, -0.08 to -0.03, -0.02 to -0.01; Z=3.42, 2.24, 4.10, 4.41, 7.77, and P=0.0006, 0.03, <0.0001, <0.0001, and <0.0001, respectively). The ACW, LV, I-Curve, IT750, AOD500, and TISA750 values showed little change (MD: 0.01, 0.05, 0.075, 0.05, -0.07, 0.02; 95% CI: -0.04 to 0.05, -0.01 to 0.11, 0 to 0.15, -0.08 to 0.17, -0.16 to 0.02, -0.03 to 0.07; Z=0.29, 1.65, 1.85, 0.72, 1.49, 0.79, and P=0.77, 0.10, 0.06, 0.47, 0.14, 0.43, respectively). DISCUSSION: The different indicators were not compared with the control group in this study, but it still could provide a reference for the selection of OCT diagnostic parameters before and after the treatment of AACG in the future.

The laser combined with intravitreal injection of ranibizumab for treatment of macular edema secondary to branch retinal vein occlusion: A protocol for systematic review and meta-analysis.

BACKGROUND: At present, laser is regarded as an effective treatment for macular edema secondary to branch retinal vein occlusion. With the breakthrough of anti-vascular endothelial growth factor drugs in ophthalmology clinical research, the intravitreal injection of ranibizumab is widely applied, but both methods have their limitations, so some clinical studies have combined and applied them together. However, the clinical results are inconsistent and controversial, and there is no relevant system evaluation for the laser combined with intravitreal injection of ranibizumab for treatment of macular edema secondary to branch retinal vein occlusion now. OBJECTIVE: Meta analysis is used to analyze and evaluate the effectiveness and safety of the laser combined with intravitreal injection of ranibizumab for treatment of macular edema secondary to branch retinal vein occlusion. METHOD: CNKI, VIP, WANFANG, China Biology Medicine disc, Web of Science, PubMed, Embase, Cochrane Library have used random controlled clinical trial of laser combined with intravitreal injection of ranibizumab for treatment of macular edema secondary to branch retinal vein occlusion from the establishment of the database to October 2020. Two researchers conducted independent screening, quality assessment and data extraction for the literatures, and used RevMan5.3 to conduct Meta analysis for the included literatures. RESULT: The research has evaluated the effectiveness and safety of the laser combined with intravitreal injection of ranibizumab for treatment of macular edema secondary to branch retinal vein occlusion through the aspects of the best corrected visual acuity 6 months after operation, macular center thickness and the incidence of adverse reactions such as elevated intraocular pressure, endophthalmitis, vitreous hemorrhage and cataract. CONCLUSION: Laser combined with intravitreal injection of ranibizumab for treatment of macular edema secondary to branch retinal vein occlusion has good effect, and the research has provided reliable evidence for the use of clinical treatment of the laser combined with intravitreal injection of ranibizumab for treatment of macular edema secondary to branch retinal vein occlusion.